Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
By M. Frank-Kamenetsky, A. Grefhorst, Norma N. Anderson, T. Racie, B. Bramlage, Akin Akinc, David Butler, K. Charissé, Robert Dorkin, Yupeng Fan and 23 more. Proceedings of the National Academy of Sciences of the United States of America, 2008
660 citations recorded by the source corpus.
Subfields: Immunology and Allergy, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/6477d264c055d035db4e444e88b83a998a5cb20c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Current prospects for RNA interference-based therapies (2011, background): “For enveloped viral vectors, such as those lentiviral systems derived from HIV, the tropism is imparted by the envelope used in vector production in a process known as pseudotyping 122 .”
- Rational design of cationic lipids for siRNA delivery (2010, methodology): “LNPs, including SNALP, have been successfully used to silence therapeutically relevant genes in nonhuman primate”
- Lipid-like materials for low-dose, in vivo gene silencing (2010, background): “It could be envisioned that the ability to regulate multiple genes may provide a powerful therapeutic approach to diseases in which multiple gene targets have already been identified (14, 19).”
- First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. (2013, methodology): “This was accompanied by the generation of specific RNAi-mediated VEGF and KSP mRNA cleavage products, as measured using the 5’ Rapid Amplification of cDNA Ends (5’ RACE) assay (13-16) (Suppl Figure 2A).”
- PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008. (2009, background): “keys reduced plasma PCSK9 levels by ?70% and plasma LDL-C levels by ?56% (41).”